Cabrellis Pharmaceuticals raises $27.5mm in Series A round
Specialty pharma company Cabrellis Pharmaceuticals (cancer drugs; a spin-off of Conforma Therapeutics) raised $27.5mm from a Series A private financing. Investors included Domain Associates, Forward Ventures, Lilly Ventures, Novo AS, ProQuest Investments, RBC Capital Partners, RiverVest Venture Partners, and SR One Ltd.
- Specialty Pharmaceuticals
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.